{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:03:49Z","timestamp":1780524229213,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK Vaccines S.r.l."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T02:45:43Z","timestamp":1480560343000},"page":"395-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Mildred A.","family":"Iro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Prymula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adefowope","family":"Odueyungbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.009_b0005","unstructured":"Meningitis B vaccine deal agreed \u2013 Jeremy Hunt 2015 [cited 2015November 19]. Available from <http:\/\/www.bbc.co.uk\/news\/health-32101921>."},{"key":"10.1016\/j.vaccine.2016.11.009_b0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.11.009_b0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.11.009_b0020","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2016.11.009_b0025","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.11.009_b0030","series-title":"33rd Annual Meeting of the European Society for Paediatric infectious diseases, Leipzig, May 2015","article-title":"Persistence of immunity following immunisation with a licensed capsular group B meningococcal vaccine in three different toddler schedules","author":"Sell","year":"2015"},{"key":"10.1016\/j.vaccine.2016.11.009_b0035","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.11.009_b0040","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.009_b0045","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.009_b0050","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.009_b0055","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.009_b0060","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5years after vaccination of toddlers and children between 12months and 10years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.11.009_b0065","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.009_b0070","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.11.009_b0075","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.11.009_b0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.009_b0085","unstructured":"JCVI position statement on the use of Bexsero\u00ae meningococcal B vaccine in the UK. London (UK): Department of health and Public Health England; 2014 [cited 2015 November 19]. Available from: <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf>."},{"key":"10.1016\/j.vaccine.2016.11.009_b0090","unstructured":"Joint Committee on Vaccination and Immunisation. Minute of the meeting on 4 February 2015 [cited 2015 November 19]. Available from: <https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/1\/2199012147\/27417264008\/1>."},{"key":"10.1016\/j.vaccine.2016.11.009_b0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W Strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.11.009_b0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/archdischild-2015-308928","article-title":"Enter B and W: two new meningococcal vaccine programmes launched","volume":"101","author":"Ladhani","year":"2016","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2016.11.009_b0105","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2015.06.079","article-title":"Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children","volume":"33","author":"Vesikari","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.009_b0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.11.009_b0115","unstructured":"Department of Health United Kingdom. Chapter 22: Meningococcal. In: Immunisation against infectious diseases\u2014\u2018The green book\u2019. 2015 [cited 2015November 19]. Available from: <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/462629\/2904512_Green_Book_Chapter_22_v6_0W.PDF>."}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2017.04.081","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16310404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:19:53Z","timestamp":1582139993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16310404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16310404"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.009","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2017.04.081","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}